Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system.

Maya W HaakerHedwig S KruitwagenArie B VaandragerMartin HouwelingLouis C PenningMartijn R MolenaarMonique E van WolferenLoes A OosterhoffBart Spee J Bernd Helms

Published in: Journal of veterinary internal medicine (2019)

Two potential drugs useful in the treatment of hepatic lipidosis in cats were identified. The drug T863 inhibits DGAT1, indicating that DGAT1 is the primary enzyme responsible for TAG synthesis from external fatty acids in cat organoids. The drug AICAR may act as a lipid-lowering compound via decreasing PLIN2 mRNA. Liver organoids can be used as an in vitro tool for drug testing in a species-specific system and provide the basis for further clinical testing of drugs to treat steatosis.

Keyphrases

fatty acid
drug induced
adipose tissue
risk assessment
high fat diet
human health
combination therapy
adverse drug
binding protein
smoking cessation